Vaccination Against Extracellular Vimentin Boosts Tumor Immune Cell Infiltration and Improves Survival of Glioma-Bearing Mice
Year: 2026
Type: dissertation
Abstract: Glioblastoma is the most common malignant primary brain tumor in adults. As approaches targeting single tumor-associated markers are hampered by heterogeneous antigen expression, new therapeutic targets are needed. Vimentin, an intermediate filament protein abundantly expressed in glioblastoma, may be secreted into the tumor microenvironment contributing to angiogenesis and immunosuppression, making it a suitable target for cancer immunotherapy. We investigated the expression of vimentin in glioblastoma at the tissue and single cell level as well as its secretion by human glioma cells in vitro. We explored the anti-tumor activity of a conjugate vaccine to induce a humoral immune response against extracellular vimentin. Vaccine efficacy was tested in both preventive and therapeutic settings which differ by whether tumor implantation occurred after or prior to immunization. Serial blood draws were performed to assess antibody titers measured by ELISA. Therapeutic vaccination was additionally evaluated in combination with local radiotherapy, CCNU or a CSF1R inhibitor, PLX3397. Vimentin was overexpressed in glioblastoma relative to non-tumor tissues and detected in conditioned media of glioma cells. Both vaccination approaches induced high anti-vimentin antibody titers, inhibited tumor growth and prolonged survival of glioma-bearing mice, with a subset of animals achieving long-term survival. Following therapy, malignant cells were subject to interferon-mediated pressure exerted by CD8+ T and NK cells. Abundant microglia and macrophages populations exhibited activation and proliferation signatures linked with pro-inflammatory signaling, consistent with an M1-like anti-tumoral phenotype. Antigen presentation genes were upregulated in dendritic cells and macrophages further supporting an immunologically active microenvironment. A temporal dynamic of immune response was observed, as end-stage tumors consistently exhibited higher immune cell infiltration following vimentin vaccination compared with mock treatment, an effect that was not observed in an early timepoint. Combination of the vimentin vaccination with CCNU or PLX3397 further improved survival outcomes as compared with mock vaccine combinations. Our findings highlight an important role for extracellular vimentin in the growth and progression of glioma and provide preclinical evidence for an approach targeting this vulnerability, which may represent a novel therapeutic option for patients with glioblastoma. embargoed until: 2027-09-20
DOI: 10.5167/uzh-437040
Author: Stanclik, Szymon Roman
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225128241
